Key Takeaways

An already approved drug might help kids with a rare bone cancer

Pazopanib extended survival in a small group of kids with Ewing sarcoma

The drug cuts off blood supply to tumors, inhibiting their growth

THURSDAY, Oct. 23, 2025 (HealthDay News) — Kids with a rare bone cancer might live longer if prescribed a drug that blocks blood supply to tumors, researchers say.

The drug pazopanib (Votrient) extended the lives of a small group of kids with Ewing sarcoma, which causes cancerous tumors in their bones, researchers report in the journal Frontiers in Oncology .

“While we wait for new treatment options, it is possible to implement this existing drug to improve outcomes in very high-risk patients,” lead researcher Anna Raciborska , head of oncology at Poland’s Warsaw

See Full Page